Nori Ebersole
Director/Board Member at SIENTRA, INC.
Net worth: 317 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Robinson | M | 54 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| James Hindman | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 36 years |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Caroline F. van Hove | F | 43 | 21 years | |
| Philippe Schaison | M | 62 | 11 years | |
| Timothy Kirk Andrews | M | 45 | 10 years | |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Cornelia Haag-Molkenteller | M | 66 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 17 years |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Ronald Menezes | M | 61 | 4 years | |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Oliver Bennett | M | 47 | 9 years | |
| Irina Erenburg | M | 54 | 3 years | |
| Ryan Kubota | M | - | - | |
| Lisa Metzner | F | 55 | 10 years | |
| Denise Dajles | F | - | 3 years | |
| Christine Ocampo | F | 51 | - | |
| Rita Karachun | F | 61 | 1 years | |
| Andrew Schmidt | M | 62 | 3 years | |
| Alexander Casdin | M | 56 | 1 years | |
| Mary Fisher | F | 62 | 5 years | |
| Brian Stevens | M | 51 |
Big Brothers Big Sisters of Orange County
| 12 years |
| Vika Brough | F | - | - | |
| Christropher Doughty | M | - | 3 years | |
| Brian R. Schaefgen | M | 53 |
Big Brothers Big Sisters of Orange County
| - |
| Allison Luo | M | 50 | 6 years | |
| Yuichiro Haruyama | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 years |
| Kenton Stewart | M | - | 4 years | |
| John Lenell | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Olivier Laurent | M | 52 | 4 years | |
| Jim Hindman | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 years |
| Jon Filderman | M | - | 1 years | |
| Jeffrey Jones | M | 68 | 5 years | |
| Timothy Ryan | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Vincent E. Mudd | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Patrick Maciariello | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Dan Carlisle | M | - | 17 years | |
| Walt Johnston | M | - | 4 years | |
| Ajay Bansal | M | 62 | 5 years | |
| Aaron Rosenberg | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Ingram | M | 61 | 19 years | |
| Ambrose Bailey | M | 60 | 6 years | |
| Keith Katkin | M | 52 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 years |
| David Hovland | M | - | 15 years | |
| Peter John McDonnell | M | 66 | 7 years | |
| Mark Mckenna | M | 44 | 4 years | |
| Paul Bisaro | M | 63 | 5 years | |
| Scott Giacobello | M | 54 | 7 years | |
| Michael R. Gallagher | M | 77 | 2 years | |
| Jeffrey Edwards | M | 63 | 22 years | |
| Brenton Saunders | M | 56 | 6 years | |
| Bryan Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Maria Hilado | F | 59 | 4 years | |
| Nicholas Simon | M | 67 | 14 years | |
| Herb Boyer | M | 87 | 19 years | |
| Vivid Sehgal | M | 56 | 8 years | |
| Sanjiv Patel | M | 50 | 11 years | |
| David Adam Buchen | M | 59 | 1 years | |
| Keith Sullivan | M | 65 | 6 years | |
| David Pyott | M | 70 | 17 years | |
| Matthew Maletta | M | 52 | - | |
| C. Nicholson | M | 69 | 6 years | |
| Nesli Basgoz | M | 66 | 6 years | |
| J. Michael Judy | M | - | 8 years | |
| Deborah Bettencourt | F | - | 15 years | |
| Les Kaplan | M | 73 | 21 years | |
| Noël Kurdi | F | - | 2 years | |
| Helen Adams | F | 65 | 2 years | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 1 years |
| Jonathon Kellerman | M | - | 6 years | |
| David Hollander | M | 50 | - | |
| Keith Marshall | M | 56 | 3 years | |
| Roger J. Lias | M | 63 | 6 years | |
| Martin Hendrix | M | 56 | 3 years | |
| William Humphries | M | 57 | 8 years | |
| Hafrun Fridriksdottir | M | 62 | 14 years | |
| Judith Swain | M | 75 | 2 years | |
| Samuel Gesten | M | 62 | 2 years | |
| Leonard Schaeffer | M | 78 | 18 years | |
| Andrew L. Turner | M | 77 | 2 years | |
| Christopher Coughlin | M | 71 | 6 years | |
| James H. Bloem | M | 73 | 5 years | |
| Christopher Bodine | M | 68 | 11 years | |
| Robert Todd Joyce | M | 66 | 1 years | |
| Roy J. Wilson | M | 68 | - | |
| Abhay Joshi | M | 61 | 5 years | |
| Patrick O’Sullivan | M | 82 | 5 years | |
| Louis Lavigne | M | 75 | 10 years | |
| John Kelly | M | 57 | 6 years | |
| Catherine Klema | F | 65 | 15 years | |
| Fred G. Weiss | M | 82 | 18 years | |
| Kevin O'Boyle | M | 68 | 9 years | |
| Tamar Howson | F | 75 | 9 years | |
| Stephen J. Ryan | M | 83 | 11 years | |
| Joseph Papa | M | 68 | 3 years | |
| Valerie J. Miller | F | 60 | 5 years | |
| Louis T. Rosso | M | - | 16 years | |
| Mary Szela | F | 60 | 2 years | |
| Sigurdur Olafsson | M | 55 | 4 years | |
| David Berk | M | 45 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| Ireland | 30 | 30.00% |
| Bermuda | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nori Ebersole
- Personal Network
